**ALKBH2 inhibition alleviates malignancy in colorectal cancer by regulating** **BMI1-mediated activation of** **NF-κB pathway**

Bingxin Ke*, Kejun Ye and Shaobing Cheng

**Abstract**

**Background:** The alkB homolog 2, alpha-ketoglutarate-dependent dioxygenase (ALKBH2) gene is involved in DNA repair and is expressed in different types of malignancies. However, the role of ALKBH2 in colorectal carcinoma (CRC) remains unclear. This study aimed to explore the potential mechanism of ALKBH2 and its function in CRC.

**Methods:** The expression levels of ALKBH2 in CRC tissues and cells were determined by qRT-PCR. Following that, the role of ALKBH2 in cell proliferation, invasion, and epithelial-mesenchymal transition (EMT) in CRC cells (Caco-2 and LOVO) were assessed by Cell Counting Kit-8 (CCK-8), transwell assays, and Western blotting, respectively. The effect of ALKBH2 on B cell-specific Moloney murine leukemia virus integration site 1 (BMI1) and downstream NF-κB pathway was determined by Western blotting and luciferase reporter assay.

**Results:** The expression of ALKBH2 was significantly upregulated both in CRC tissues and cells. Further experiments demonstrated that reduction of ALKBH2 suppressed Caco-2 and LOVO cell proliferation and invasion. Moreover, ALKBH2 knockdown also suppressed EMT, which increased E-cadherin expression and reduced N-cadherin expression. Besides, ALKBH2 silencing inhibited BMI1 expression and reduced nuclear accumulation of the NF-κB p65 protein, as well as the luciferase activity of NF-κB p65. Upregulation of BMI1 reversed the effect of ALKBH2 knockdown on the proliferation and invasion in CRC cells.

**Conclusions:** Our findings suggest that suppression of ALKBH2 alleviates malignancy in CRC by regulating BMI1-mediated activation of NF-κB pathway. ALKBH2 may serve as a potential treatment target for human CRC.

**Keywords:** Colorectal carcinoma, alkB homolog 2, Alpha-ketoglutarate dependent dioxygenase, B cell-specific Moloney murine leukemia virus integration site 1, NF-κB pathway

**Background**

Colorectal carcinoma (CRC) is one of the most common malignant tumors worldwide [1], ranking the third highest incidence of all malignant tumors and the fourth highest mortality rate after lung cancer, liver cancer, and gastric cancer [2]. Study demonstrated that metastasis is the leading cause of death in CRC patients [3].

Approximately 65% of patients with CRC are affected by metastasis at the time of diagnosis or will develop metastasis later; the liver is mostly involved (40–60%) in a synchronous or metachronous manner, but only 25% of hepatic metastatic lesions are resectable at the first evaluation [4, 5]. Clinically, micrometastasis failed to be detected in most patients undergoing radical surgery. This is one of the primary causes that lead to failed surgical therapy and subsequent tumor recurrence [6]. The occurrence of CRC is a complex biological process caused by the imbalance of various tumor-associated...
genes. Thus, in-depth knowledge of the molecular mechanism of CRC occurrence and development is of great scientific significance and clinical value for early diagnosis, diacritics, and target therapy of CRC.

AlkB protein is a repair dioxygenase that reverses alkyl DNA bases by an α-ketoglutarate/Fe(II)-dependent mechanism [7]. The ALKBH protein family is highly expressed in all kinds of human malignant tumors and has been implicated in tumor progression and development. To date, eight mammalian homologues, human AlkB homologues 1–8, have been identified by bioinformatic analysis [8, 9]. Only two of the corresponding human proteins, hABH2 and hABH3, have been shown to possess a similar repair activity as AlkB from Escherichia coli [10]. ALKBH2 is a housekeeping enzyme, which protects the mammalian genome from 1-meA damage by repairing the damage in double-stranded DNA (dsDNA) [11]. Wu et al. reported that ALKBH2 knockdown enhanced the cisplatin sensitivity in H1299 lung carcinoma cells [11]. Fujiy and his colleagues demonstrated that ALKBH2 is overexpressed in bladder cancer [12]. Moreover, ALKBH2 knockdown restrains epithelial to mesenchymal transition (EMT), which increases E-cadherin expression and reduces vimentin expression [12]. The DNA repair enzyme ALKBH2 is implicated in both tumorigenesis and resistance to chemotherapy in cancers [13]. However, the effects of ALKBH2 on the progression of CRC and the molecular mechanisms underlying metastasis remain unclear.

The B cell-specific Moloney murine leukemia virus integration site 1 (BMI1) protein is one of the polycomb group (PcG) family of proteins [14]. Recently, researchers have found that BMI-1 oncogene-driven pathway plays an important part in tumor development and metastases [15], and BMI-1 overexpression has been demonstrated in many carcinomas. Song et al. have proven that upregulation of BMI1 increases the motility and invasiveness of human nasopharyngeal epithelial cells, while BMI1 knockdown decreases cell motility [16]. In addition, in vivo studies reported the upregulation of BMI1 in cancer tissues and are associated with remote metastases of gastric [17], ovarian [18], breast [19], pancreatic [20], and primary hepatocellular carcinoma (HCC) [21]. Furthermore, BMI1 overexpression has also been found in patients with lymphoma [22], chronic myeloid leukemia [23], and acute myeloid leukemia [24].

Here, the biological roles of ALKBH2 in CRC were investigated. Our findings showed that ALKBH2 is significantly over-expressed in CRC tissues and cells. Besides, ALKBH2 knockdown inhibits CRC cell (Caco-2 and LOVO) proliferation, invasion, and EMT. Further studies have found that ALKBH2 affects the proliferation and aggressive progression of CRC cells through regulating BMI1 expression as well as the downstream NF-κB pathway. Thus, these results suggest that ALKBH2 stimulates CRC metastasis and invasion by regulating the activation of BMI1-mediated NF-κB pathway, which may be an oncogene involved in the evolution and invasive development of CRC.

Methods
Patients and specimens
Colorectal cancer tissues (N = 39) and para-carcinoma tissues (> 2 cm away from the tumor, N = 33) were obtained from CRC patients, who underwent surgical operations in the First Affiliated Hospital, College of Medicine, Zhejiang University. All patients were diagnosed by histology, and none of the patients received chemotherapy or radiotherapy before operation. Tissues were preserved in liquid nitrogen for subsequent experiments. This study was approved by the Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University. Consents were obtained from all participants before the study commenced. This study was performed in accordance with the World Medical Association Declaration of Helsinki [25].

Cell culture
Human CRC cell lines (Caco-2, SW480, HCT15, HT-29, SW837, and LOVO) and normal colorectal epithelium cell line (CDD-18Co) [26] were received from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in RPMI 1640 or DMEM medium (GIBCO-BRL) containing 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin and incubated at 37 °C, 5% CO2. After 2–3 stable generations, logarithmic-phased cells were used in subsequent experiments.

Cell transfection
Cells were transfected with specific shRNA oligonucleotides using Lipofectamine® 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocols. The ALKBH2-targeting shRNA (shALKBH2) and the negative non-targeting control, shNC, used in this study were synthesized by Invitrogen. The sequence of shALKBH2 is as follows (5’ to 3’): CCGGGTGCTC
ACACAGGTATAAACCTGAGTTTATACCTGT
TGATGAGCACTTTTTG. To construct BMI1-overexpressing plasmids, BMI1 cDNA was cloned into p-MSCV-IRES-GFP. For transfection, cells were seeded in 6-well plates and cultured for 24 h until cells reached 70–80% confluence. Then, cells were transfected with 2μg of plasmid using Lipofectamine® 2000 (Invitrogen) following the manufacturer’s instructions.
RNA extraction and qRT-PCR
Total RNA was extracted from tissues or cultured cells using the TRIzol reagent (Invitrogen, USA), according to manufacturer’s protocols. A First Strand cDNA Synthesis Kit (Takara, Dalian, China) was used for reverse transcription with random primers. qRT-PCR was carried out using SYBR Premix Ex Taq (Takara, USA), following the manufacturer’s instructions on an ABI 7500 real-time PCR system (Applied Biosystems, USA). The primer sequences are shown in Table 1. GAPDH expression was used as a reference. Three experimental triplicates were performed.

Cell proliferation assay
Cell proliferation was assessed by Cell Counting Kit-8 assays (CCK-8; Dojindo Molecular Technologies, Japan). The transfected cells (Caco-2 and LOVO) were cultured in 96-well plates (5 × 10^3 cells/well). Then, each well was incubated with CCK-8 reagent at 0, 24, 48, 72, and 96 h, and cells were further cultured for 2 h at 37 °C. Absorbance at 450 nm was read using a microplate reader. All tests were repeated three times.

Cell migration and invasion assays
Cell migration analysis was performed using the transwells (8-mm pore size, Corning, USA). For invasion assays, the upper surface of the membrane was coated with Matrigel (BD Biosciences, USA) at 37 °C for 4 h, whereas for the migration assay, the top chamber uncoated. A total of 2 × 10^4 cells in 200 μL of serum-free medium were seeded onto the upper chamber of transwell plates. The lower chamber was supplemented with medium containing 10% FBS. After 24 h of incubation, cells in the upper chambers were removed by a cotton swab, whereas cells that migrated into the lower chamber were immobilized by cold methanol and stained with 0.1% crystal violet. All migrated and invaded cells were visualized under a light microscope and manually counted in at least ten random regions for each transwell membrane.

Western blotting
Proteins were extracted from cells using RIPA buffer (Beyotime, Haimen, China) containing 1% protease inhibitor cocktail (Roche, Diagnostics GmbH, Mannheim, Germany) and phenylmethylsulfonyl fluoride (PMSF; Roche). Then, proteins were separated by SDS-PAGE and transferred onto nitrocellulose membranes (Sigma-Aldrich). Membranes were blocked with 5% milk in Tris-buffered saline (TBS) for 1 h at 25 °C, followed by incubation with primary antibodies: anti-ALKBH2 (1:1000; Invitrogen), anti-TGFβ2, anti-Smad3, anti-pSmad3, anti-N-cadherin, anti-E-cadherin, anti-Vinmentin, anti-Snail1, and anti-Slug (all 1:1000; Cell Signaling Technology) at 4 °C overnight. Next, membranes were incubated with secondary antibodies (HRP-conjugated 1:5000; Santa Cruz Biotechnology) at 37 °C for 2 h. Lastly, protein bands of interest were visualized and imaged by ECL method using the Bio-Rad imaging system. Protein band intensities were quantified using ImageJ software [27]. For nuclear protein extraction, nuclear and cytoplasmic proteins were separated using Solarbio.

Immunohistochemistry
Immunohistochemistry (IHC) was performed for normal tissues as previously described [28, 29]. Briefly, paraffin sections were incubated with anti-ALKBH2 (1:100; Santa Cruz Bio, Bath, UK) at 4 °C overnight, followed by 30-min incubation at 25 °C with goat anti-rabbit Envision System Plus-HRP (Dako Cytomation). After washing with PBS for 3 times, samples were incubated with DAB for 1 min and counterstained with Mayer hematoxylin, dehydrated, and fixed. PBS was used as the negative control.

Luciferase reporter assay
Luciferase reporter assay was used to assess the expression of target genes. First, pRL-TK renilla luciferase plasmids, firefly luciferase reporter plasmids, and pNF-κB luciferase plasmid were co-transfected in cells. Luciferase activity was detected using a Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA). The transfection efficiency data were normalized by differentiating firefly luciferase activity with renilla luciferase activity.

Statistical analysis
SPSS 17.0 software package (IBM, Chicago, IL) was used for statistical analysis. Results are shown as mean ± standard deviation (SD). When comparing two groups, Student’s t test was used to compare the differences, whereas one-way ANOVA analysis was used when comparing multiple groups. P value < 0.05 was considered as statistically significant.

Table 1 The specific primer pairs used in quantitative real-time RT-PCR

| Genes | Primers | Sequences |
|-------|---------|-----------|
| ALKBH2 | Forward | 5′-GACTGGACAGACCTTCAAC-3′ |
|        | Reverse  | 5′-AGGGAGACAGAGGCAATGG-3′ |
| BMI1  | Forward | 5′-ATGCATCGAACAACGAGAATCAAGATCACT-3′ |
|        | Reverse  | 5′-TCAACCAGAAGAAGTTGCTGACCC-3′ |
| GAPDH | Forward | 5′-GGAGCGAGATCCCTCCAAAAT-3′ |
|        | Reverse  | 5′-GGCTGTTGTCATACTTCTCATGG-3′ |
**Results**

**ALKBH2 is overexpressed in CRC tissues and cells**

The transcript levels and distribution of ALKBH2 in 39 CRC and 33 para-carcinoma tissues were detected by qRT-PCR and immunohistochemistry, respectively. As shown in Fig. 1a, the mRNA levels of ALKBH2 were significantly increased in CRC tissues compared to that of control. Consistently, ALKBH2 staining demonstrated a higher percentage of ALKBH2-positive cells in CRC tissues compared to para-carcinoma control tissues (Fig. 1b). In addition, the expression of ALKBH2 was detected in normal gastric epithelial cell line (CCD-18Co) and different CRC cell lines (Caco-2, HCT116, SW480, HT-29, SW837, SW620, LOVO, and HCT15). qRT-PCR assay showed that ALKBH2 expression was higher in all colorectal carcinoma cells compared with normal colorectal epithelial cells (Fig. 1c). These findings revealed the overexpression of ALKBH2 in CRC tissues and cells.

**ALKBH2 knockdown inhibits CRC cell proliferation**

Following the finding of ALKBH2 overexpression in CRC tissues and cells, we next sought to determine the effects of ALKBH2 silencing on CRC cell proliferation. ALKBH2 expression was silenced by RNA interference. qRT-PCR analysis and Western blotting results demonstrated that ALKBH2 mRNA and protein expression were significantly reduced in cells transfected with sh-ALKBH2 compared to sh-NC group (Fig. 2a, b). Moreover, CCK-8 analysis showed that knockdown of ALKBH2 significantly inhibited cell viability in both Caco-2 and LOVO cell lines (Fig. 2c). These results...

---

**Fig. 1** ALKBH2 is upregulated in CRC tissues and cells. **a** Relative ALKBH2 expression in CRC tissues (N = 39) and paracarcinoma (N = 33), quantified using qRT-PCR assays. **P < 0.01** vs. paracarcinoma. The mRNA levels of ALKBH2 are significantly increased in CRC tissues compared to that of control. **b** Representative IHC images showing ALKBH2 staining in CRC and paracarcinoma. **P < 0.01** vs. paracarcinoma. The percentage of ALKBH2-positive cells is higher in CRC tissues than para-carcinoma. **c** ALKBH2 expression in CRC lines (Caco-2, HCT116, SW480, HT-29, SW837, SW620, LOVO, and HCT15) compared to the colorectal cell (GES-1) as quantified using qRT-PCR assays. ALKBH2 is highly expressed in all colorectal carcinoma cells compared with normal colorectal epithelial cells.
Fig. 2 (See legend on next page.)
suggested that ALKBH2 knockdown inhibited proliferation of CRC cells.

ALKBH2 knockdown inhibits CRC cell migration and invasion via EMT signaling pathway

Transwell assays were used to evaluate the effect of ALKBH2 on the migration and invasion of Caco-2 and LOVO cells. Results from the transwell assays revealed a significant reduction in the number of migrated and invaded cells in cells transfected with sh-ALKBH2 compared with the sh-NC group (Fig. 3a). Epithelial-to-mesenchymal transition (EMT) is considered to be an important mechanism for human tumor metastasis [30]. In order to determine the association between ALKBH2 and the EMT pathway, Western blot analysis was performed to measure the expression of EMT-related signaling molecules in Caco-2 and LOVO cells transfected with sh-ALKBH2 or sh-NC. E/N-cadherin switch mediates cancer progression via TGF-β-induced EMT [31]. The results revealed that knockdown of ALKBH2 increased E-cadherin expression and reduced N-cadherin level (Fig. 3b), suggesting that ALKBH2 knockdown suppressed the migration and invasion of CRC cells via EMT signaling pathway.

ALKBH2 regulates the expression of BMI and the NF-κB pathway

To further explore the role of ALKBH2 in the pathogenesis of CRC, we next investigated the effects of ALKBH2 silencing on BMI1 expression and the downstream NF-κB pathway in Caco-2 and LOVO cells. qRT-PCR analysis showed that the mRNA levels of BMI1 were significantly downregulated in ALKBH2-silenced cells (Fig. 4a). Consistently, as shown in Fig. 4b, the protein expression of BMI1 was also downregulated in the sh-ALKBH2 group compared with the sh-NC group. Reduction in BMI1 expression was reversed at both mRNA and protein levels by overexpression of BMI1 (Fig. 4c, d). Since the transcriptional activity of NF-κB is indicated by nuclear accumulation of NF-κB, we next investigated whether ALKBH2 deficiency alters the levels of nuclear NF-κB p65, a catalytic component of NF-κB. As displayed in Fig. 4e, ALKBH2 knockdown by shRNA inhibited nuclear accumulation of the NF-κB p65...
protein, whereas overexpression of BMI1 led to opposite effect. The effect of ALKBH2 knockdown on p65 nuclear translocation was further validated using dual-luciferase assays. It was found that the luciferase activity in sh-ALKBH2 treatment group showed a significant reduction in nuclear p65, while BMI1 overexpression led to a prominent increase in nuclear p65 (Fig. 4f). These results suggested that ALKBH2 regulates the expression of BMI1 and the downstream NF-κB pathway.

Upregulation of BMI1 reverses the effect of ALKBH2 knockdown on CRC cell proliferation and invasion

Next, the results from the CCK-8 and transwell assays demonstrated that BMI1 overexpression reversed the...
effects of sh-ALKBH2 on cell proliferation (Fig. 5a) and invasion (Fig. 5b) in CRC cells, respectively. In addition, upregulation of BMI1 increased N-cadherin expression and reduced E-cadherin level (Fig. 5c). These results suggested that upregulation of BMI1 could reverse the effects of ALKBH2 silencing on the proliferation and invasion of CRC cells.

**Discussion**

CRC is one of the most frequent causes of death worldwide. Thus, identification of new therapeutic target is critical for the therapy of CRC to improve the survival rate in CRC patients. The ALKBH2 gene is involved in DNA repair and is expressed in many malignancies. However, the role of ALKBH2 in the pathogenesis of CRC remains unclear. This study explored for the first time the functions and clinical significance of ALKBH2 in CRC.

The oxidases of the AlkB family represent a new class of DNA base repair enzymes that employ oxidative dealkylation mechanism. The ALKBH protein families are highly expressed in all kinds of human malignant tumors, and they are implicated in tumor progression and development. Shimada et al. reported that ALKBH8 promotes the progression of human urinary tract epithelial cancer by downregulating NAD(P)H oxidase-1 (NOX-1).
and by subsequently activating c-jun NH(2)-terminal kinase (JNK) and p38 NADPH oxidase 1-dependent reactive oxygen species to induce apoptosis [32]. Moreover, upregulation of ALKBH3 is implicated in the development of non-small cell lung cancer and prostate cancer [33]. However, ALKBH2 has been less studied in tumors and has not been studied in CRC. This is the first study that investigated the role of ALKBH2 in CRC. The findings from this study have demonstrated that ALKBH2 was overexpressed in CRC, and it promoted cell proliferation, metastasis, and invasion. In addition, we have shown that ALKBH2 silencing inhibited EMT, which increased E-cadherin expression and reduced N-cadherin level. Increasing data have indicated that cells with EMT phenotype consist of a plentiful of tumor stem cells with cytotoxic injury-induced repair signals, proposing a biological connection between EMT and DNA repair system. EMT offers the most suitable microenvironment for DNA repair molecules to carry out their functions. Interestingly, the findings from this study have also shown that ALKBH2 knockdown decreased BMI1 expression and inhibited nuclear accumulation of the NF-κB p65 protein, as well as the luciferase activity of NF-κB p65.

The carcinogenic features of BMI1 have linked BMI1 expression to cancer development and clinical prognosis of human tumors (Table 2). Studies have demonstrated that BMI1 can regulate cancer initiation and cell transformation [16, 34]. Li et al. have reported that BMI1 exerts glioma cells apoptotic resistance via the activation of NF-κB-mediated pathway [35]. Our study showed a concurrent decrease in the expression of BMI1 and

| Characteristics          | Total of patients | ALKBH2 Low expression (≤ median) | ALKBH2 High expression (> median) | P value |
|--------------------------|-------------------|----------------------------------|----------------------------------|---------|
| Number                   | 33                | 17                               | 16                               |         |
| Gender                   |                   |                                  |                                  | 0.392   |
| Male                     | 21                | 12                               | 9                                |         |
| Female                   | 12                | 5                                | 7                                |         |
| Ages (years)             |                   |                                  |                                  | 0.325   |
| < 65                     | 22                | 10                               | 12                               |         |
| ≥ 65                     | 11                | 7                                | 4                                |         |
| Tumor site               |                   |                                  |                                  | 0.114   |
| Colon                    | 21                | 13                               | 8                                |         |
| Rectum                   | 12                | 4                                | 8                                |         |
| Tumor size(cm)           |                   |                                  |                                  | 0.387   |
| < 5                      | 17                | 10                               | 7                                |         |
| ≥ 5                      | 16                | 7                                | 9                                |         |
| Pathological T category  |                   |                                  |                                  | 0.009*  |
| T1-T2                    | 20                | 13                               | 5                                |         |
| T3-T4                    | 13                | 4                                | 11                               |         |
| Lymph node metastasis    |                   |                                  |                                  | 0.026*  |
| N0                       | 26                | 16                               | 10                               |         |
| N1-N2                    | 7                 | 1                                | 6                                |         |
| Distant metastasis       |                   |                                  |                                  | 0.028*  |
| M0                       | 30                | 17                               | 12                               |         |
| M1                       | 3                 | 0                                | 4                                |         |
| TNM stage                |                   |                                  |                                  | 0.021*  |
| I–II                     | 21                | 14                               | 7                                |         |
| III–IV                   | 12                | 3                                | 9                                |         |
| Differentiation          |                   |                                  |                                  | 0.353   |
| Well/moderate            | 20                | 9                                | 11                               |         |
| Poor                     | 13                | 8                                | 5                                |         |

*p < 0.05
nuclear NF-κB (the p65 submit), which demonstrated that BM11 reinforced NF-κb transcriptional activity through accelerating nuclear translocation of NF-κB. In addition, upregulation of BM11 reversed the impact of ALKBH2 knockdown on cell proliferation, invasion, and EMT in CRC cells. This has not only confirmed our results, but also supports the mechanistic data, indicating that ALKBH2 downregulation inhibited BM11 expression and suppressed CRC proliferation. Increased ALKBH2/BMI1 expression is closely associated with transformation from a noninvasive to an invasive phenotype. Molecular therapy focusing on ALKBH2 may represent an attractive tool to achieve successful therapy in the treatment of human CRC.

Conclusion

In conclusion, this study showed that suppression of ALKBH2 alleviated malignancy in CRC by regulating BM11-mediated activation of NF-κB pathway. ALKBH2 may serve as a potential target for the development and progression of human CRC.

Abbreviations

CRC: Colorectal cancer; EMT: Epithelial-mesenchymal transition; BM11: B cell-specific Moloney murine leukemia virus integration site 1; dsDNA: Double-stranded DNA; PcG: Polycomb-group; DMEM: Dulbecco’s modified Eagle medium; FBS: Fetal bovine serum; CCK 8: Cell Counting Kit 8; qRT-PCR: Quantitative real-time PCR; HCC: Hepatocellular carcinoma

Acknowledgements

Not applicable.

Authors’ contributions

Bingxian Ke designed the study, supervised the data collection, and analyzed the data; Kejun Ye interpreted the data and prepare the manuscript for publication; Shaobing Cheng supervised the data collection, analyzed the data, and reviewed the draft of the manuscript. All authors have read and approved the manuscript.

Funding

Not applicable.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate

Ethical approval was obtained from the Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University.

Consent for publication

Written informed consent was obtained from a legally authorized representative(s) for anonymized patient information to be published in this article.

Competing interests

The authors state that there are no conflicts of interest to disclose.

Received: 6 August 2020 Accepted: 2 December 2020

Published online: 10 December 2020

References

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012. v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No.11. Lyon, France: International Agency for Research on Cancer; 2013.

2. Brenner H, Kloor M, Poix CP. Colorectal cancer. Lancet. 2014;383(9927):1490–502.

3. Goldstein DA, Zeichner SB, Bartnik CM, Neustadter E, Flowers CR. Metastatic colorectal cancer: a systematic review of the value of current therapies. Clin Colorectal Cancer. 2016;15(1):1–6 PMID:PMC4744531.

4. Calon A, Espinet E, Palomo-Ponce S, Tautello DV, Iglesias M, Cespedes MV, et al. Dependency of colorectal cancer on a TGF-beta-driven program of stromal cells for metastasis initiation. Cancer Cell. 2012;22(5):571–84 PMID:PMC3512565.

5. Dahan L, Norguet E, Etienne-Grimaud MC, Formento JL, Gasi M, Nanni I, et al. Pharmacogenotypic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer. 2011;11:496 PMID:PMC35235081.

6. Serabio A, Palojarinis P, Pulighe F, Moro S, Bono-Roseella V, Attene F, et al. Impact of novel histopathological factors on the outcomes of liver surgery for colorectal cancer metastases. Eur J Surg Oncol. 2016;42(9):1268–77.

7. Chen F, Tang Q, Bian K, Humlock ZT, Yang X, Jost M, et al. Adaptive response enzyme AlkB preferentially repairs 1-methylguanine and 3-methylthymine adducts in double-stranded DNA. Chem Res Toxicol. 2016;29(6):887–93 PMID:PMC5497687.

8. Delaney JC, Eissmann JM. Mutagenesis, genotoxicity, and repair of 1-methyladenine, 3-alkylcytosines, 1-methylguanine, and 3-methylthymine in alkB Escherichia coli. Proc Natl Acad Sci U S A. 2004;101(39):14051–6.

9. Kurowski MA, Bhagwat AS, Papaj G, Bujnicki JM. Phylogenomic identification of five new human homologs of the DNA repair enzyme AlkB. BMC Genomics. 2003;4(1):48 PMID:PMC317286.

10. Duncan T, Trewick SC, Koivisto P, Bates PA, Lindahl T, Sedgwick B. Reversal of DNA alkylation damage by two human dioxygenases. Proc Natl Acad Sci U S A. 2002;99(26):16660–5 PMID:PMC1939200.

11. Wu SS, Xu W, Liu S, Chen B, Wang XL, Wang Y, et al. Down-regulation of ALKBH2 alleviated malignancy in CRC by regulating Ezh2 is strongly expressed in aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2. Virchows Arch. 2013;463(5):697–711.

12. Fujii T, Shimada K, Anai S, Fujimoto K, Konishi N. ALKBH2, a novel AlkB homologue, contributes to human bladder cancer progression by regulating MUC1 expression. Cancer Sci. 2013;104(3):321–7.

13. Wilton DL, Beharry AA, Srivastava A, O’Connor TR, Kool ET. Fluorescence probes for ALKBH2 allow the measurement of DNA alkylation repair and drug resistance responses. Angew Chem Int Ed Engl. 2018;57(39):12896–900 PMID:PMC6478024.

14. Wang MC, Li CL, Cui J, Jiao M, Wu T, Jing L, et al. BM1-1, a promising therapeutic target for human cancer. Oncol Lett. 2015;10(2):583–8 PMID:PMC4506079.

15. Gavrilescu WM, Todosi AM, Antei MG, Filip B, Scripcariu V. Expression of bm-1 protein in cervical, breast and ovarian cancer. Rev Med Chir Soc Med Nat Iasi. 2012;116(4):1112–7.

16. Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, et al. The polycomb group protein bm-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest. 2009;119(2):3626–36 PMID:PMC2786794.

17. Yang DD, Cui BB, Sun LY, Zheng HQ, Huang Q, Tong JX, et al. The co-expression of USP22 and BM1-1 may promote cancer progression and predict therapy failure in gastric carcinoma. Cell Biochem Biophys. 2011;61(3):703–10.

18. Yang GF, He WP, Cai MY, He LR, Luo JH, Deng DX, et al. Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma. BMC Cancer. 2010;10:133 PMID:PMC2858112.

19. Guo BH, Feng Y, Zhang R, Xu LH, Li MZ, Kung HF, et al. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer. 2011;10(1):10 PMID:PMC3038148.

20. Weng CC, Hsiao MJ, Wu CC, Lin YC, Shan YS, Hung WC, et al. Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer. Mol Cancer. 2019;18:328 PMID:PMC6526617.

21. Li X, Yang Z, Song W, Zhou L, Li Q, Tao K, et al. Overexpression of Bmi-1 contributes to the invasion and metastasis of hepatocellular carcinoma by increasing the expression of matrix metalloproteinase (MMP)2, MMP-9 and vascular endothelial growth factor via the PTEN/PI3K/Akt pathway. Int J Oncol. 2013;43(3):793–802.

22. Abd Al Kader L, Oka T, Takata K, Sun X, Sato H, Murakami I, et al. In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2. Virchows Arch. 2013;463(5):697–711.
23. Mohty M, Yong AS, Szydlo RM, Apperley JF, Melo JV. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood. 2007;110(1):380–3.

24. Chowdhury M, Mihara K, Yasunaga S, Ohtaki M, Takihara Y, Kimura A. Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia. 2007;21(5):1116–22.

25. Available N. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2000;284(23):3043–5.

26. Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ, et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis. 2010;31(3):350–8.

27. Aryal P, Kim K, Park PH, Ham S, Cho J, Song K. Baicalein induces autophagic cell death through AMPK/ULK1 activation and downregulation of mTORC1 complex components in human cancer cells. FEBS J. 2014;281(20):4644–58.

28. Wu G, Chen Z, Li J, Ye F, Chen G, Fan Q, et al. NOTCH4 is a novel prognostic marker that correlates with colorectal cancer progression and prognosis. J Cancer. 2018;9(12):2374–9 PMID:30365718.

29. Xie J, Zhuo Y, Zheng Y, Mo R, Liu ZL, Li BW, et al. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer. Int Urol Nephrol. 2017;49(5):817–23.

30. Zhang M, Huang S, Long D. MiR-381 inhibits migration and invasion in human gastric carcinoma through downregulated SOX4. Oncol Lett. 2017;14(3):3760–6 PMID:2880589.

31. Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, et al. E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer. 2011;105(12):1885–93 PMID:22111878.

32. Shimada K, Nakamura M, Anai S, De Velasco M, Tanaka M, Tsujikawa K, et al. A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progression. Cancer Res. 2009;69(7):3157–64.

33. Tasaki M, Shimada K, Kimura H, Tsujikawa K, Konishi N. ALKBH3, a human AlkB homologue, contributes to cell survival in human non-small-cell lung cancer. Br J Cancer. 2011;104(4):700–6 PMID:21049579.

34. Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J, et al. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene Bmi-1. Mol Cancer. 2011;10:99 PMID:PMID:3173388.

35. Li J, Gong LY, Song LB, Jiang LL, Liu LP, Wu J, et al. Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor-kappaB Pathway. Am J Pathol. 2010;176(2):699–709 PMID:PMID:2808077.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.